undefined undefined
NaN.000
NaN.00%
Madrigal Pharmaceuticals (NASDAQ:MDGL) said that its recently approved NASH/MASH drug Rezdiffra is now available in the US through a specialty pharmacy network. Rezdiffra, also known as resmetirom, re...
04-09 22:03
MILWAUKEE, April 2, 2024 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Akero (Nasdaq: AKRO). The investigation results from inaccurate statements Akero ...
04-03 06:05
继降糖、减重之后,又一几乎“无药可救”的代谢病迎来首款新药获批。 近年来,患脂肪肝这一“富贵病”的人群愈发广泛,四个成年人中可能就有一个受脂肪肝困扰。其中,发展...
03-16 19:26
格隆汇3月14日|纳斯达克生物科技指数跌1.6%,成分股和黄医药ADR(HCM)跌9.21%目前表现最差,据媒体消息,该公司向苏慰国授出合共135.96万份认股...
03-14 22:16
The comnay announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $29.00 per share. All of the shares in the offering are being offered by
03-06 15:16
UBS analyst Eliana Merle maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target from $39 to $42.
03-05 22:43
Akero Therapeutics success in HARMONY Phase 2b study for efruxifermin. EFX demonstrated sustained efficacy and well-tolerance, marking a major milestone in liver disease treatment.
03-05 00:28
AKRO: 99% | Akero Therapeutics Released Preliminary Topline Week 96 Results From HARMONY Phase 2B Study Of Efruxifermin For Pre-Cirrhotic Metabolic Dysfunction-associated Steatohepatitis, Fibrosis Stage 2 Or
03-04 21:47